The Study of Soy Isoflavones in Asthma

Study Overview
=================
Brief Summary
-----------------
The trial is designed to study the effects of soy supplements on asthma control.

Detailed Description
-----------------
Asthma is a common disease that has a major impact on morbidity and health care costs. Although the prevalence and severity of asthma have increased over the last several decades, the specific causes remain unknown. One possible mechanism is a change in diet. Yet, epidemiological and interventional studies designed to identify a key nutrient or antioxidant vitamin that may be responsible for the increase in disease severity have produced inconsistent results. A recent pilot study showed a soy isoflavone supplement reduces exhaled nitric oxide (FeNO) and ex vivo LTC4 synthesis in patients with inadequately controlled asthma. This clinical trial is designed to test the novel hypothesis that dietary supplementation with soy isoflavones is an effective treatment in patients with poorly controlled asthma. The study will include 380 patients with low dietary soy intake, 12 years of age or older, who are taking either inhaled corticosteroids or leukotriene modifiers and have inadequately controlled asthma. Participants will be randomly assigned to treatment with either a soy isoflavone supplement (containing genistein, daidzein and glycitein; 100 mg daily of the glycoside forms) or placebo for six months. The results of this trial will increase understanding of the role of diet in asthma; could identify a novel, safe and relatively inexpensive treatment for patients with asthma; and potentially will have a substantial impact on public health in the United States.

Official Title
-----------------
The Study of Soy Isoflavones in Asthma

Conditions
-----------------
Asthma

Intervention / Treatment
-----------------
* Drug: Soy isoflavone supplement
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 12 or older Physician diagnosed asthma FEV1 equal or greater than 50% predicted pre-bronchodilator At least 12% increase in FEV1 15-3 minutes after inhaling 2-4 puffs of albuterol or positive methacholine challenge (20% fall in FEV1 at less than 8 mg/mL). Either of these can be available from the previous 2 years Currently prescribed daily controller asthma medication Poor asthma control (at least one of the following) A score of 1.5 or greater on the Juniper Asthma Control Questionnaire Use of beta-agonist for asthma symptoms two or more times per week Nocturnal awakening with asthma symptoms more than once per week Two or more episodes of asthma symptoms in the past 12 months with each requiring at least one of the following: emergency department visit, unscheduled physician visit, prednisone course, hospitalization Smoking status Non-smoker for 6 months or longer Less than 10 pack-years smoking history Exclusion Criteria: Pulmonary function FEV1 less than 50% predicted pre-bronchodilator Other major chronic illnesses Conditions which in the judgment of the study physician would interfere with participation in the study, e.g., non-skin cancer, endocrine disease, coronary artery disease, severe hypertension, immunodeficiency states History of thyroid disease, breast cancer, ovarian, or endometrial cancer History of physician diagnosis of chronic bronchitis, emphysema, or COPD Medication use Current consumption of soy isoflavone supplements Oral corticosteroid use within the past 6 weeks Use of tamoxifen Use of an investigational treatment in the previous 30 days Drug allergy Known adverse reaction to genistein, other phytoestrogens, or soy products Females of childbearing potential Pregnant or lactating. Participants must agree to use effective contraception during the trial. Non-adherence Inability or unwillingness to provide consent or, in the case of children, inability or unwillingness of the child to provide assent Inability to swallow study medication Inability to perform baseline measurements Completion of less than 10 of the last 14 days diary entries during screening period Inability to be contacted by telephone Intention to move out of the area within 6 months Other Recent asthma exacerbation (within 6 weeks) Recent upper respiratory infection (within 2 weeks) Body weight less than 77 pounds (35 kg) Intake of soy or soy-enriched foods 1 or more times a week Change in diet over the past month or expected change in diet during the study

Ages Eligible for Study
-----------------
Minimum Age: 12 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Soy Isoflavone<br>Oral isoflavone supplement (100 mg/day) | Drug: Soy isoflavone supplement<br>* Oral soy isoflavone supplement (100 mg/day)<br>* Other names: Soy supplement;|
| Placebo Comparator: Placebo<br>Matching placebo | Drug: Placebo<br>* Placebo<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mean Change From Baseline to 24 Weeks for FEV1 |  | 24 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Soy, Asthma, Supplement, ACRC, SOYA